Mode
Text Size
Log in / Sign up
N/A N=2,050 Randomized Double-blind Prevention

Genetic Testing to Understand and Address Renal Disease Disparities

Hypertension · Chronic Kidney Disease · Genomics

Enrolled (actual)
2,050
Serious AEs
0.0%
Results posted
Oct 2020
Primary outcome: Primary: Number of Participants With Urine Protein Excretion — 33; 278; 39; 50 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Immediate Genetic Testing (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Icahn School of Medicine at Mount Sinai
Primary completion
Jan 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Urine Protein Excretion
33; 278; 39; 50; 377; 68
PRIMARY
Change in Systolic Blood Pressure
-3; -3; -6
SECONDARY
Number of Participants With Change in Medication Adherence
146; 53; 68; 21
SECONDARY
Number of Patients With Changes in Psychosocial Behaviors
547; 129
SECONDARY
Number of Participants With Attitude Towards Genetic Testing
1425; 208; 1391; 203; 1420; 211

Summary

In this genomic medicine implementation pilot project, the investigators aim to conduct a randomized trial in a network of community health centers and primary care facilities to study processes, effects and challenges of incorporating information for apolipoprotein L1 (APOL1)-attributable genetic risk for end stage kidney disease in patients of African ancestry with hypertension .

Eligibility Criteria

Inclusion Criteria

  • Ages18-65
  • Self-identifies as Black/African American
  • History of hypertension
  • Patient at a participating site

Exclusion Criteria

  • History of Chronic Kidney Disease
  • History of Diabetes
  • Pregnant
  • Cognitively impaired/unable to provide consent
  • Terminally ill
  • Planning to leave area of study permanently during the one year study period
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02234063). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search